Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Key trials in bladder cancer from ASCO GU 2022

Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, discusses some of the key trial data presented at ASCO GU 2022, including the EV-103 trial on enfortumab vedotin for muscle invasive bladder cancer (NCT03288545), as well as the potential of PARP inhibitors in this field. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.